UCLA Invents Newsletter
Newsletter published by: UCLA OIP-ISR June 2014


June 06, 2014
FirstFridays @OIP-ISR
Topic:   "1st Annual UCLA "Code for the Mission" App Competition."

June 11, 2014
LAVA's First Look LA 2014
Topic:  "Advancing the culture of innovation in SoCal: First Look at 50 emerging..."

More Events


Dear Colleagues,

With the publication of the FY13 University of California Report on Technology Transfer, I want to highlight and celebrate the achievements of UCLA last year. Relative to our UC peers, we are at or near the top of all major metrics for one of the largest university systems in the world:
  • #1 in inventions reported, patents filed, US patents issued, letter of intent agreements, and startups launched
  • #2 in licenses executed, licensing income, and financial distributions to campus and inventors
  • 2 of the top 5 royalty-producing inventions for UC
These results speak to the first-class research ongoing at UCLA, as well as senior leadership’s commitment to foster an entrepreneurial culture on campus.

In FY2014, we expect the trend to continue, with more disclosures, more licenses, and more sponsored research and licensing income to campus. For context, we expect to launch more research-based startups in FY2014 than Stanford or MIT.

Finally, I want to thank the staff of OIP-ISR for their contributions, and their continued commitment to making UCLA a singular institution for translating research for the benefit of society.


Brendan Rauw
Associate Vice Chancellor and Executive Director of Entrepreneurship
UCLA Office of Intellectual Property & Industry Sponsored Research


UC FY13 Tech-Transfer Report:  UCLA #1 in Startups
In FY 2013, UC researchers submitted 1,727 new inventions; entered into 427 new IP licensing agreements; and launched 71 new startup companies. UCLA ranked highest in these and other technology transfer metrics featured in the report.

UCLA Startup, ImaginAb, Raise $21M Series B Financing

ImaginAb has raised $21 million in additional venture funding to advance its antibody-re-engineering technology, a biotech approach to imaging that the company believes will help personalize treatments for cancer and immune disease.

UCLA Licensee, Kite Pharma, Seeks $115 Million in IPO

Santa Monica-based Kite Pharma, a biopharmaceuticals firm focused on treating cancer, has filed for an IPO, saying in the SEC filing that it is looking to raise $115M in its offering.

UCLA Innovation Featured at UC-wide Tech Forum
20 University of California inventors presented their innovative research at UC’s annual Technology Commercialization Forum held recently in SF. The work spanned a huge array of fields and came from eight UC campuses and LBNL.

 Intellectual Property Announcements

New U.S. Patents Awarded

  • 8,734,799 - Unconjugated anti-TfR antibodies and compositions thereof for the. . . | M. Penichet, et al.
  • 8,728,744 - Salivary protein biomarkers for human oral cancer  | D. Wong, et al.
  • 8,728,361 - Making nanostructured porous hollow spheres with tunable structure  | Y. Lu, et al.
  • 8,717,437 - End-to-end visual recognition system and methods  | S. Soatto, et al.
  • 8,716,246 - Azuvirin peptides  | R. Lehrer, et al.
  • 8,703,920 - Fully human antibodies against N-cadherin | R. Reiter, et al.


New UCLA Technologies Available for Licensing



'Roundup:  UCLA Startup Funding and IP Licensing Highlights
NEW for Entrepreneurs and Company Executives

UCLA TechMatch

A customized, automated service that matches your
technology interest areas with UCLA innovation

UCLA Invents Newsletter, Vol. 2, No. 10

How to Subscribe

View Newsletter Archive

Send editorial comments and corrections to:  
Bob Nidever, Editor,  bnidever@research.ucla.edu

Contributors: Neil Bajpayee, Ben Dibling, Howard Chang

UCLA Invents is published by the UCLA Office of Intellectual Property & Industry Sponsored Research
11000 Kinross Ave., Suite 200; Los Angeles, CA 90095 | tel. 310-794-0558 | http://oip.ucla.edu

Copyright © 2014 The Regents of the University of California. All Rights Reserved.

Share this